DDInter1628 DDInter1948
Ruxolitinib, formerly known as INCB018424 or INC424, is an anticancer drug and a Janus kinase (JAK) inhibitor. It is a potent and selective inhibitor of JAK1 and JAK2, which are tyrosine kinases involved in cytokine signalling and hematopoiesis. Myeloproliferative neoplasms, such as myelofibrosis and polycythemia vera, are often characterized by aberrant activation of the JAK-STAT pathway, leading to abnormal blood cell counts and thrombotic complications. By inhibiting JAK1 and JAK2, ruxolitinib works to block the dysregulated cell signalling pathways and prevents abnormal blood cell proliferation. Due to a large number of patients with myeloproliferative neoplasms who have JAK2 mutations, ruxolitinib was the first ATP-competitive inhibitor of JAK1 and JAK2 ever developed. Rux
Vortioxetine is an antidepressant medication indicated for the treatment of major depressive disorder (MDD). It is classified as a serotonin modulator and stimulator (SMS) as it has a multimodal mechanism of action towards the serotonin neurotransmitter system whereby it simultaneously modulates one or more serotonin receptors and inhibits the reuptake of serotonin. More specifically, vortioxetine acts via the following biological mechanisms: as a serotonin reuptake inhibitor (SRI) through inhibition of the serotonin transporter, as a partial agonist of the 5-HT1B receptor, an agonist of 5-HT1A, and an antagonist of the 5-HT3, 5-HT1D, and 5-HT7 receptors. SMSs were developed because there are many different subtypes of serotonin receptors, however, not all of these receptors appear to be involved in the antidepressant effects of SRIs. Some serotonin receptors seem to play a relatively neutral or insignificant role in the regulation of mood, but others, such as 5-HT1A autoreceptors and 5-HT7 receptors, appear to play an oppositional role in the efficacy of SRIs in treating depression.
Ruxolitinib {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Prasugrel
Prasugrel {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Vortioxetine
Ruxolitinib {u} (Compound) causes {v} (Side Effect) Gastrointestinal disorder
Gastrointestinal disorder {u} (Side Effect) is caused by {v} (Compound) Prasugrel
Prasugrel {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Vortioxetine
Ruxolitinib {u} (Compound) causes {v} (Side Effect) Hypercholesterolaemia
Hypercholesterolaemia {u} (Side Effect) is caused by {v} (Compound) Sibutramine
Sibutramine {u} may lead to a major life threatening interaction when taken with {v} Vortioxetine
Ruxolitinib {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Doxepin
Doxepin {u} may lead to a major life threatening interaction when taken with {v} Vortioxetine
Ruxolitinib {u} (Compound) downregulates {v} (Gene) HDAC6
HDAC6 {u} (Gene) is upregulated by {v} (Compound) Treprostinil
Treprostinil {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Vortioxetine
Ruxolitinib {u} (Compound) binds {v} (Gene) PLK1
PLK1 {u} (Gene) is upregulated by {v} (Compound) Treprostinil
Treprostinil {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Vortioxetine
Ruxolitinib {u} (Compound) binds {v} (Gene) PLK1
PLK1 {u} (Gene) is downregulated by {v} (Compound) Dasatinib
Dasatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Vortioxetine
Ruxolitinib {u} (Compound) binds {v} (Gene) PLK1
PLK1 {u} (Gene) is downregulated by {v} (Compound) Terbinafine
Terbinafine {u} may lead to a major life threatening interaction when taken with {v} Vortioxetine
Ruxolitinib {u} (Compound) downregulates {v} (Gene) HDAC6
HDAC6 {u} (Gene) is downregulated by {v} (Compound) Bupropion
Bupropion {u} may lead to a major life threatening interaction when taken with {v} Vortioxetine
Ruxolitinib {u} (Compound) upregulates {v} (Gene) UBQLN2
UBQLN2 {u} (Gene) is upregulated by {v} (Compound) Treprostinil
Treprostinil {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Vortioxetine
Ruxolitinib (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Prasugrel (Compound) and Prasugrel may cause a moderate interaction that could exacerbate diseases when taken with Vortioxetine
Ruxolitinib (Compound) causes Gastrointestinal disorder (Side Effect) and Gastrointestinal disorder (Side Effect) is caused by Prasugrel (Compound) and Prasugrel may cause a moderate interaction that could exacerbate diseases when taken with Vortioxetine
Ruxolitinib (Compound) causes Hypercholesterolaemia (Side Effect) and Hypercholesterolaemia (Side Effect) is caused by Sibutramine (Compound) and Sibutramine may lead to a major life threatening interaction when taken with Vortioxetine
Ruxolitinib (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Doxepin (Compound) and Doxepin may lead to a major life threatening interaction when taken with Vortioxetine
Ruxolitinib (Compound) downregulates HDAC6 (Gene) and HDAC6 (Gene) is upregulated by Treprostinil (Compound) and Treprostinil may cause a moderate interaction that could exacerbate diseases when taken with Vortioxetine
Ruxolitinib (Compound) binds PLK1 (Gene) and PLK1 (Gene) is upregulated by Treprostinil (Compound) and Treprostinil may cause a moderate interaction that could exacerbate diseases when taken with Vortioxetine
Ruxolitinib (Compound) binds PLK1 (Gene) and PLK1 (Gene) is downregulated by Dasatinib (Compound) and Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Vortioxetine
Ruxolitinib (Compound) binds PLK1 (Gene) and PLK1 (Gene) is downregulated by Terbinafine (Compound) and Terbinafine may lead to a major life threatening interaction when taken with Vortioxetine
Ruxolitinib (Compound) downregulates HDAC6 (Gene) and HDAC6 (Gene) is downregulated by Bupropion (Compound) and Bupropion may lead to a major life threatening interaction when taken with Vortioxetine
Ruxolitinib (Compound) upregulates UBQLN2 (Gene) and UBQLN2 (Gene) is upregulated by Treprostinil (Compound) and Treprostinil may cause a moderate interaction that could exacerbate diseases when taken with Vortioxetine